Adagene Inc. (ADAG) details six-month 2025 results in new Form 6-K filing

Rhea-AI Filing Summary

Adagene Inc. has furnished a Form 6-K as a foreign private issuer to provide its financial results for the six-month period ended June 30, 2025. The submission points readers to two key exhibits: a press release discussing the six-month 2025 financial results and corporate update, and unaudited interim condensed consolidated financial statements for the six months ended June 30, 2024 and 2025.

The company also states that this Form 6-K, including Exhibits 99.1 and 99.2, is incorporated by reference into its existing registration statements on Form F-3 and Form S-8, so these updated results and disclosures are now legally part of those offering documents unless later superseded.

2025-06-30--12-31Q220250001818838false00018188382025-01-012025-06-300001818838us-gaap:AdditionalPaidInCapitalMember2025-01-012025-06-300001818838us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-300001818838us-gaap:CommonStockMember2024-01-012024-06-300001818838us-gaap:CommonStockMember2025-01-012025-06-300001818838us-gaap:RetainedEarningsMember2025-06-300001818838us-gaap:AdditionalPaidInCapitalMember2025-06-300001818838us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001818838us-gaap:RetainedEarningsMember2024-12-310001818838us-gaap:AdditionalPaidInCapitalMember2024-12-310001818838us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001818838us-gaap:TreasuryStockCommonMember2024-06-300001818838us-gaap:RetainedEarningsMember2024-06-300001818838us-gaap:AdditionalPaidInCapitalMember2024-06-300001818838us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001818838us-gaap:TreasuryStockCommonMember2023-12-310001818838us-gaap:RetainedEarningsMember2023-12-310001818838us-gaap:AdditionalPaidInCapitalMember2023-12-310001818838us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001818838us-gaap:CommonStockMember2025-06-300001818838us-gaap:CommonStockMember2024-12-310001818838us-gaap:CommonStockMember2024-06-300001818838us-gaap:CommonStockMember2023-12-310001818838srt:MinimumMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberadag:PerformanceIncentivePlan2021Member2025-01-012025-06-300001818838srt:MaximumMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberadag:PerformanceIncentivePlan2021Member2025-01-012025-06-300001818838srt:MinimumMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberadag:PerformanceIncentivePlan2021Member2024-01-012024-06-300001818838srt:MaximumMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberadag:PerformanceIncentivePlan2021Member2024-01-012024-06-3000018188382023-01-012023-12-310001818838us-gaap:ShareBasedPaymentArrangementNonemployeeMemberadag:PerformanceIncentivePlan2021Member2025-05-012025-05-310001818838us-gaap:ShareBasedPaymentArrangementEmployeeMemberadag:PerformanceIncentivePlan2021Member2025-01-012025-06-300001818838us-gaap:ShareBasedPaymentArrangementEmployeeMemberadag:PerformanceIncentivePlan2021Member2024-01-012024-06-300001818838adag:ModificationOfVestingSchedulesAndConditionsOfShareOptionsMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2022-01-072022-01-070001818838adag:SanofiAgreementMember2025-01-012025-06-300001818838adag:GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember2025-01-012025-06-300001818838adag:ExelixisIncAgreementMember2025-01-012025-06-300001818838adag:SanofiAgreementMember2024-01-012024-06-300001818838adag:GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember2024-01-012024-06-300001818838adag:ExelixisIncAgreementMember2024-01-012024-06-300001818838adag:DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember2024-01-012024-06-300001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember2025-01-012025-06-300001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember2025-01-012025-06-300001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember2025-01-012025-06-300001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.EightMember2025-01-012025-06-300001818838adag:BorrowingsFromBankOfJiangsuCo.LtdTwoMember2025-01-012025-06-300001818838adag:BorrowingsFromBankOfJiangsuCo.LtdOneMember2025-01-012025-06-300001818838adag:BorrowingsFromAgriculturalBankOfChinaLimitedTwoMember2025-01-012025-06-300001818838adag:BorrowingsFromAgriculturalBankOfChinaLimitedThreeMember2025-01-012025-06-300001818838adag:BorrowingsFromAgriculturalBankOfChinaLimitedOneMember2025-01-012025-06-300001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember2024-01-012024-12-310001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember2024-01-012024-12-310001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember2024-01-012024-12-310001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember2024-01-012024-12-310001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.EightMember2024-01-012024-12-310001818838adag:BorrowingsFromBankOfJiangsuCo.LtdTwoMember2024-01-012024-12-310001818838adag:BorrowingsFromBankOfJiangsuCo.LtdOneMember2024-01-012024-12-310001818838adag:BorrowingsFromAgriculturalBankOfChinaLimitedTwoMember2024-01-012024-12-310001818838adag:BorrowingsFromAgriculturalBankOfChinaLimitedThreeMember2024-01-012024-12-310001818838adag:BorrowingsFromAgriculturalBankOfChinaLimitedOneMember2024-01-012024-12-310001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember2023-01-012023-12-310001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember2023-01-012023-12-310001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember2023-01-012023-12-310001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember2023-01-012023-12-310001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.EightMember2023-01-012023-12-310001818838adag:BorrowingsFromAgriculturalBankOfChinaLimitedTwoMember2023-01-012023-12-310001818838adag:BorrowingsFromAgriculturalBankOfChinaLimitedThreeMember2023-01-012023-12-310001818838adag:BorrowingsFromAgriculturalBankOfChinaLimitedOneMember2023-01-012023-12-310001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember2022-01-012022-12-310001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember2022-01-012022-12-310001818838adag:WuxiBiologicsCaymanInc.Memberadag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember2025-01-012025-06-300001818838adag:WuxiApptecGroupMemberadag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember2025-01-012025-06-300001818838adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember2025-01-012025-06-300001818838adag:CertainSeniorManagementPersonnelMember2025-01-012025-06-300001818838adag:WuxiBiologicsCaymanInc.Memberadag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember2024-01-012024-06-300001818838adag:WuxiApptecGroupMemberadag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember2024-01-012024-06-300001818838adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember2024-01-012024-06-300001818838adag:CertainSeniorManagementPersonnelMember2024-01-012024-06-300001818838srt:MinimumMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2025-06-300001818838srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2025-06-300001818838srt:MaximumMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2025-06-300001818838srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2025-06-300001818838us-gaap:VehiclesMember2025-06-300001818838us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2025-06-300001818838us-gaap:MachineryAndEquipmentMember2025-06-300001818838us-gaap:LeaseholdImprovementsMember2025-06-300001818838us-gaap:FurnitureAndFixturesMember2025-06-300001818838adag:ElectronicEquipmentMember2025-06-300001818838us-gaap:VehiclesMember2024-12-310001818838us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-12-310001818838us-gaap:MachineryAndEquipmentMember2024-12-310001818838us-gaap:LeaseholdImprovementsMember2024-12-310001818838us-gaap:FurnitureAndFixturesMember2024-12-310001818838adag:ElectronicEquipmentMember2024-12-310001818838adag:CertainSeniorManagementPersonnelMember2024-12-310001818838adag:WuxiBiologicsCaymanInc.Member2025-06-300001818838adag:WuxiApptecGroupMember2025-06-300001818838adag:CertainSeniorManagementPersonnelMember2025-06-300001818838adag:WuxiBiologicsCaymanInc.Member2024-12-310001818838adag:WuxiApptecGroupMember2024-12-310001818838us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-06-300001818838us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-06-300001818838us-gaap:RetainedEarningsMember2025-01-012025-06-300001818838us-gaap:RetainedEarningsMember2024-01-012024-06-300001818838adag:AdageneSuzhouLimitedMember2025-06-300001818838adag:AdagenePte.Ltd.Member2025-06-300001818838adag:AdageneProjectC1Pte.Ltd.Member2025-06-300001818838adag:AdageneIncorporatedMember2025-06-300001818838adag:AdageneHongKongLimitedMember2025-06-300001818838adag:AdageneAustraliaPtyLtd.Member2025-06-300001818838adag:AdageneAgMember2025-06-300001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember2025-06-300001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember2025-06-300001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.EightMember2025-06-300001818838adag:BorrowingsFromAgriculturalBankOfChinaLimitedTwoMember2025-06-300001818838adag:BorrowingsFromAgriculturalBankOfChinaLimitedThreeMember2025-06-300001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember2024-12-310001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember2024-12-310001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember2024-12-310001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.EightMember2024-12-310001818838adag:BorrowingsFromBankOfJiangsuCo.LtdTwoMember2024-12-310001818838adag:BorrowingsFromBankOfJiangsuCo.LtdOneMember2024-12-310001818838adag:BorrowingsFromAgriculturalBankOfChinaLimitedTwoMember2024-12-310001818838adag:BorrowingsFromAgriculturalBankOfChinaLimitedThreeMember2024-12-310001818838adag:BorrowingsFromAgriculturalBankOfChinaLimitedOneMember2024-12-3100018188382021-01-012021-12-3100018188382024-01-012024-12-3100018188382022-01-012022-12-310001818838adag:BorrowingsFromBankOfNingboCo.LtdMember2024-09-012024-09-300001818838adag:ChinaConstructionBankCorporationMember2024-06-012024-06-300001818838adag:BorrowingsFromBankOfNingboCo.LtdMember2023-07-012023-07-310001818838adag:ChinaEverbrightBankCorporationMember2023-03-012023-03-310001818838adag:BorrowingsFromBankOfNingboCo.LtdMember2023-01-012023-01-310001818838adag:BorrowingsFromBankOfNingboCo.LtdMember2024-09-300001818838adag:ChinaConstructionBankCorporationMember2024-06-300001818838adag:BorrowingsFromBankOfJiangsuCo.LtdTwoMember2023-09-300001818838adag:BorrowingsFromBankOfJiangsuCo.LtdOneMember2023-08-310001818838adag:BorrowingsFromBankOfNingboCo.LtdMember2023-07-310001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.EightMember2023-04-300001818838adag:ChinaEverbrightBankCorporationMember2023-03-310001818838adag:BorrowingsFromBankOfNingboCo.LtdMember2023-01-310001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember2022-11-300001818838adag:BorrowingsFromAgriculturalBankOfChinaLimitedThreeMember2022-11-300001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember2022-08-310001818838adag:BorrowingsFromAgriculturalBankOfChinaLimitedTwoMember2022-08-310001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember2022-05-310001818838adag:BorrowingsFromAgriculturalBankOfChinaLimitedOneMember2022-05-310001818838adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember2021-09-300001818838adag:SecondSupplierMemberus-gaap:CostOfGoodsProductLineMemberus-gaap:SupplierConcentrationRiskMember2025-01-012025-06-300001818838adag:PerformanceIncentivePlan2021Member2021-01-1600018188382024-06-3000018188382023-12-310001818838adag:OutsideMainlandOfChinaMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:GeographicConcentrationRiskMember2025-06-300001818838adag:MainlandOfChinaMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:GeographicConcentrationRiskMember2025-06-300001818838adag:OutsideMainlandOfChinaMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:GeographicConcentrationRiskMember2024-12-310001818838adag:MainlandOfChinaMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:GeographicConcentrationRiskMember2024-12-310001818838us-gaap:StockCompensationPlanMember2025-01-012025-06-300001818838us-gaap:StockCompensationPlanMember2024-01-012024-06-300001818838us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-06-300001818838us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-06-300001818838us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001818838us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001818838dei:AdrMemberus-gaap:IPOMember2021-02-210001818838us-gaap:SubsequentEventMember2025-07-012025-07-310001818838adag:PerformanceIncentivePlan2021Member2021-01-162021-01-160001818838adag:ModificationOfVestingSchedulesAndConditionsOfShareOptionsMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2022-01-070001818838adag:OneSupplierMemberus-gaap:CostOfGoodsProductLineMemberus-gaap:SupplierConcentrationRiskMember2025-01-012025-06-300001818838adag:OneSupplierMemberus-gaap:CostOfGoodsProductLineMemberus-gaap:SupplierConcentrationRiskMember2024-01-012024-06-300001818838adag:SanofiAgreementMember2022-03-310001818838us-gaap:SubsequentEventMember2025-07-3100018188382024-01-012024-06-300001818838us-gaap:FairValueMeasurementsNonrecurringMember2025-06-300001818838us-gaap:FairValueMeasurementsNonrecurringMember2024-12-310001818838adag:SingleReportableSegmentMember2025-01-012025-06-300001818838adag:SingleReportableSegmentMember2024-01-012024-06-300001818838adag:SanofiAgreementMember2023-01-012023-12-310001818838adag:SanofiAgreementMember2022-03-012022-03-310001818838adag:ExelixisIncAgreementMember2022-01-012022-12-310001818838adag:ExelixisIncAgreementMember2022-04-300001818838adag:ExelixisIncAgreementMember2021-02-280001818838adag:ExelixisIncAgreementMember2023-01-012023-12-310001818838adag:DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember2023-01-012023-12-310001818838adag:DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember2025-01-012025-06-300001818838adag:GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember2018-12-012018-12-3100018188382025-06-3000018188382024-12-31iso4217:USDiso4217:CNYadag:itemxbrli:pureiso4217:USDxbrli:sharesxbrli:sharesadag:segment

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

​

FORM 6-K

​

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-
16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

​

For the Month of August 2025

​

Commission File Number: 001-39997

Adagene Inc.

4F, Building C14, No. 218

Xinghu Street, Suzhou Industrial Park

Suzhou, Jiangsu Province, 215123

People’s Republic of China

+86-512-8777-3632

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

​

​

​

​

​

INCORPORATION BY REFERENCE

​

On August 12, 2025, Adagene Inc. (the “Company”) reported the Company’s financial results for the six-month period ended June 30, 2025. This current report on Form 6-K, including Exhibits 99.1 and 99.2 attached hereof, is hereby incorporated by reference into the registration statements on Form F-3 (File No. 333-287161) and Form S-8 (File No. 333-255250) of the Company (including any prospectuses forming a part of such registration statements), and shall be a part thereof from the date on which this current report is furnished, to the extent not superseded by documents

or reports subsequently filed or furnished.

​

​

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​	Adagene Inc.
​	​
​	By:	/s/ Peter Luo
​	Name:	Peter Luo
​	Title:	Chief Executive Officer
​	​
Date: August 12, 2025	​

​

​

​

​

EXHIBIT INDEX

​

​	​	​
Exhibit		Description
​	​	​
99.1	​	Press release tilted “Adagene Reports Six Month 2025 Financial Results and Provides Corporate Update”
99.2	​	Unaudited Interim Condensed Consolidated Financial Statements for the six months ended June 30, 2024 and 2025
101.INS	​	Inline XBRL Instance Document – this instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH	​	Inline XBRL Taxonomy Extension Schema
101.CAL	​	Inline XBRL Taxonomy Extension Calculation Linkbase
101.DEF	​	Inline XBRL Taxonomy Extension Definition Linkbase
101.LAB	​	Inline XBRL Taxonomy Extension Label Linkbase
101.PRE	​	Inline XBRL Taxonomy Extension Presentation Linkbase
104	​	Cover Page Interactive Data File (embedded within the Inline IXBRL document)

​

​

​

​

FAQ

What does Adagene Inc. (ADAG) report in this Form 6-K?

The company furnishes a Form 6-K to report its financial results for the six-month period ended June 30, 2025, along with a related corporate update.

Which financial period is covered by Adagene Inc.'s attached statements?

The unaudited interim condensed consolidated financial statements cover the six months ended June 30, 2024 and 2025.

What key exhibits are included with Adagene Inc.'s August 2025 Form 6-K?

Exhibit 99.1 is a press release titled “Adagene Reports Six Month 2025 Financial Results and Provides Corporate Update,” and Exhibit 99.2 contains the unaudited interim condensed consolidated financial statements for the six months ended June 30, 2024 and 2025.

How does this Form 6-K affect Adagene Inc.'s existing registration statements?

The company states that this Form 6-K, including Exhibits 99.1 and 99.2, is incorporated by reference into its registration statements on Form F-3 (File No. 333-287161) and Form S-8 (File No. 333-255250).

Who signed Adagene Inc.'s Form 6-K for the six months ended June 30, 2025?

The Form 6-K is signed on behalf of Adagene Inc. by Peter Luo, who is identified as the Chief Executive Officer.

Does this Form 6-K include detailed financial figures for Adagene Inc.?

Specific financial figures are contained in the attached Exhibits 99.1 and 99.2, which include the press release and the unaudited interim condensed consolidated financial statements.